HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has reaffirmed its Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and increased its price target from $42.00 to $50.00. Tarsus Pharmaceuticals' stock has risen 9.18% in the last 24 hours to $17.00 per share. The new price target suggests a potential upside of 194.12% from the current price. Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focusing on ophthalmic conditions, with its lead candidate TP-03 targeting Demodex blepharitis.
November 10, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Tarsus Pharmaceuticals and raises the price target to $50, indicating a significant potential upside. The stock has already reacted positively, increasing by 9.18%.
The reaffirmation of a Buy rating and an increased price target by a reputable analyst firm like HC Wainwright & Co. typically instills confidence in investors and can lead to a positive short-term impact on the stock price. The stock's recent 9.18% rise reflects the market's initial positive reaction to the news. The substantial potential upside of 194.12% from the current price to the new target suggests that the stock may continue to experience upward momentum as investors adjust their valuations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100